Is your firm in the Top 3 of Google Search?
Our comprehensive SEO program is designed to get you in the Top 3 Google Search results and keep you there. Contact us today for a complimentary audit and review.
This site uses features not supported by Internet Explorer.
Heading into the new year, here’s a look back at takeaways from 2018, including the Top Mass Tort list, and overall breakout of top practice area spend. We’ll also look at trends heading into 2019. Based on media spend at CAMG, there are 4 new additions to the Mass Torts List. Valsartan, Attune Knee, Gadolinium, and Hip have all made a big presence in the past quarter. Talc and Invokana have also made big news. Reuter’s uncovered Johnson & Johnson documents that reveal the company has been aware of asbestos in its talc products as far back as 1971 – and has hidden test results from regulators and the public. Amidst dropping shares, Johnson & Johnson continues to assert its talc products are safe but stay tuned for a possible impact on future verdicts.
On the bad drug front, the latest injury linked to diabetes medication Invokana is necrotizing fasciitis, also known as “genital gangrene.” 39% of Invokana callers have responded “yes” to experiencing this potentially life-threatening bacterial infection.
*January 2018 - December 2018. Source: CAMG Cumulative Campaign Data
*Q4 (October 2018 - December 2018) compared to Q3 (July 2018 - September 2018)
Whether your 2019 plans include improving your existing mass tort campaigns or starting with new ones, contact CAMG today.